ReproCELL Inc. (JP:4978)

:4978

4978

ReproCELL Inc.

RESEARCH TOOLSreports

Want to see JP:4978 full AI Analyst Report?

ReproCELL Inc. (4978) Price & Analysis

0 Followers

4978 Stock Chart & Stats

¥143.00

¥3.00(2.91%)

At close: Jan 08 4:00 PM EST

¥143.00

¥3.00(2.91%)

Day’s Range― - ―

52-Week Range¥135.00 - ¥242.00

Previous CloseN/A

Volume331.50K

Average Volume (3M)510.74K

Market Cap

¥16.84B

Enterprise Value¥14.02B

Total Cash (Recent Filing)¥4.72B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)120.8

Beta0.59

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.29

Shares Outstanding95,147,890

10 Day Avg. Volume504,660

30 Day Avg. Volume510,736

Financial Highlights & Ratios

PEG Ratio-0.33

Price to Book (P/B)1.52

Price to Sales (P/S)4.58

P/FCF Ratio-169.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)1.7

Revenue Forecast (FY)¥3.53B

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet (near-zero Debt)Near-zero debt and steadily growing equity provide durable financial flexibility, lowering solvency risk and enabling the company to fund R&D, platform development, or selective M&A without immediate reliance on external financing. This structural strength supports multi‑month investment plans.

Profitability Inflection And Stronger Gross MarginA clear inflection to positive net income and a ~9 percentage point gross margin expansion indicate improving unit economics driven by product mix or pricing power. Sustained higher gross margins create room to absorb SG&A and R&D, improving long‑term operating leverage.

Niche IPSC And Contract Services Business ModelSpecialization in iPSC products and contract services targets structural demand from drug discovery and disease modeling. The combination of product sales and recurring service contracts builds diversified, sticky revenue streams and raises barriers to entry over months to years.

Bears Say

Weak Cash Generation / Negative Free Cash FlowPersistently negative free cash flow constrains the company’s ability to self‑fund growth and R&D. Even with improving accounting earnings, the cash shortfall may force equity or debt financing, diluting capital returns or increasing fixed obligations over a multi‑month horizon.

Operating Profit Still Negative (EBIT Loss)Despite net income turning positive, core operations remain unprofitable, implying reliance on non‑operating items or one‑time factors. Without sustainable operating profitability, margin improvement and cash conversion risk stalling once those items normalize.

Low Return On Equity And Uneven Revenue HistoryVery low ROE signals weak capital efficiency and a long runway to generate meaningful shareholder returns. Coupled with historically uneven revenue trends, it raises uncertainty that recent profitability gains will translate into consistent, durable growth and higher returns.

4978 FAQ

What was ReproCELL Inc.’s price range in the past 12 months?

ReproCELL Inc. lowest stock price was ¥135.00 and its highest was ¥242.00 in the past 12 months.

What is ReproCELL Inc.’s market cap?

ReproCELL Inc.’s market cap is ¥16.84B.

When is ReproCELL Inc.’s upcoming earnings report date?

ReproCELL Inc.’s upcoming earnings report date is May 20, 2026 which is in 27 days.

How were ReproCELL Inc.’s earnings last quarter?

ReproCELL Inc. released its earnings results on Feb 12, 2026. The company reported ¥0.29 earnings per share for the quarter, beating the consensus estimate of N/A by ¥0.29.

Is ReproCELL Inc. overvalued?

According to Wall Street analysts ReproCELL Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ReproCELL Inc. pay dividends?

ReproCELL Inc. does not currently pay dividends.

What is ReproCELL Inc.’s EPS estimate?

ReproCELL Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ReproCELL Inc. have?

ReproCELL Inc. has 95,147,890 shares outstanding.

What happened to ReproCELL Inc.’s price movement after its last earnings report?

ReproCELL Inc. reported an EPS of ¥0.29 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.829%.

Which hedge fund is a major shareholder of ReproCELL Inc.?

Currently, no hedge funds are holding shares in JP:4978

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ReproCELL Inc.

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.